Citations

Clear

862 citation(s) found for "Habermann, EB".

Length of Stay After Overlapping Surgery
Hyder, Joseph A. , Habermann, Elizabeth B. , Habermann, Elizabeth , Cima, Robert R.

Mayo Clinic

JAMA | December 5, 2017 | Volume: 318 | Issue: 21 | Pages: 2140

10.1001/jama.2017.16607 | PMID 29209713 Get It

Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma
García, Héctor Alexander Velásquez , Spinelli, John J., Gaffney, Patrick M. , Smedby, Karin E. , Wang, Sophia , Adami, Hans‐Olov , Angelucci, Emanuele , Ansell, Stephen M. , Asmann, Yan W. , Becker, Nikolaus, Benavente, Yolanda , Berndt, Sonja I. , Bertrand, Kimberly A. , Birmann, Brenda M. , Boeing, Heiner , Bracci, Paige M. , Brennan, Paul , Brooks‐Wilson, Angela , Clavel, Jacqueline , Conde, Lucía , Cotenbader, Karen H, Cox, David G. , Crouch, Simon , Roos, Anneclaire J. De , Sanjosé, Sílvia de , Lollo, Simonetta Di, Diver, W. Ryan , Foretová, Lenka , Ghesquières, Hervé , Glimelius, Bengt , Haïoun, Corinne , Hartge, Patricia, Hjalgrim, Henrik , Holford, Theodore R. , Holly, Elizabeth A., Jackson, Rebecca D. , Kaaks, Rudolph, Kane, Eleanor , Klein, Robert J. , Kraft, Peter , Kricker, Anne , Lan, Qing , Lawrence, Charles , Liebow, Mark , Lightfoot, Tracy, Link, Brian K. , Maynadié, Marc, McKay, James , Melbye, Mads , Molina, Thierry Jo , Monnereau, Alain , Morton, Lindsay M. , Nieters, Alexandra, Novak, Anne J. , Offit, Kenneth , Purdue, Mark P. , Rais, Marco, Riby, Jacques, Roman, Eve , Rothman, Nathaniel , Salles, Gilles , Severi, Gianluca , Severson, Richard K., Skibola, Christine F., Smith, Martyn T. , Southey, Melissa C. , Staines, Anthony , Thompson, Carrie A. , Tilly, Hervé , Tinker, Lesley F. , Tjønneland, Anne , Turner, Jennifer , Vajdic, Claire M. , Vermeulen, Roel , Vijai, Joseph , Vineis, Paolo , Virtamo, Jarmo, Wang, Zhaoming , Weinstein, Stephanie J. , Zheng, Tongzhang, Zucca, Mariagrazia, Clarke, Ann E. , Smith, Alexandra , Bertrand, Kimberly A , Turner, Jennifer , Link, Brian K , Joseph, Vijai , Southey, Melissa C , Brooks-Wilson, Angela R , Vajdic, Claire M , Kane, Eleanor , Tjønneland, Anne , Wang, Zhaoming , Severi, Gianluca , Kraft, Peter , Morton, Lindsay M , De Roos, Anneclaire J , Salles, Gilles A , Wang, Sophia S , Birmann, Brenda M , Roman, Eve , Clavel, Jacqueline , Smith, Alexandra , Bernatsky, Sasha , Ramsey‐Goldman, Rosalind , Albanes, Demetrius , Boffetta, Paolo , Cerhan, James R. , Chanock, Stephen Jacob , Cozen, Wendy , Doǧan, Ahmet , Giles, Graham G. , Habermann, Thomas M. , Kelly, Rachel S. , North, Kari E. , Slager, Susan L. , Smith, Alex, Teras, Lauren R. , Witzig, Thomas E. , Zelenetz, Andrew D. , Zeleniuch‐Jacquotte, Anne , Zhang, Yawei , Angelucci, Emanuele , Klein, Robert

Mayo Clinic

Lupus Science & Medicine | November 13, 2017 | Volume: 4 | Issue: 1 | Pages: e000187

10.1136/lupus-2016-000187 | PMID 29214033 Get It

Objective Determinants of the increased risk of diffuse large B-cell lymphoma (DLBCL) in SLE are unclear. Using data from a recent lymphoma genome-wide association study (GWAS), we assessed whether certain lupus-related single nucleotide polymorphisms (SNPs) were also associated with DLBCL. Methods GWAS data on European Caucasians from the International Lymphoma Epidemiology Consortium (InterLymph) provided a total of 3857 DLBCL cases and 7666 general-population controls. Data were pooled in a random-effects meta-analysis. Results Among the 28 SLE-related SNPs investigated, the two most convincingly associated with risk of DLBCL included the CD40 SLE risk allele rs4810485 on chromosome 20q13 (OR per risk allele=1.09, 95% CI 1.02 to 1.16, p=0.0134), and the HLA SLE risk allele rs1270942 on chromosome 6p21.33 (OR per risk allele=1.17, 95% CI 1.01 to 1.36, p=0.0362). Of additional possible interest were rs2205960 and rs12537284. The rs2205960 SNP, related to a cytokine of the tumour necrosis factor superfamily TNFSF4, was associated with an OR per risk allele of 1.07, 95% CI 1.00 to 1.16, p=0.0549. The OR for the rs12537284 (chromosome 7q32, IRF5 gene) risk allele was 1.08, 95% CI 0.99 to 1.18, p=0.0765. Conclusions These data suggest several plausible genetic links between DLBCL and SLE.
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia
Abeykoon, Jithma P. , Paludo, Jonas , King, Rebecca L. , Ansell, Stephen M. , LaPlant, Betsy, Halvorson, Alese E. , Gonsalves, Wilson I. , Dingli, David , Lacy, Martha Q. , He, Rong , Kourelis, Taxiarchis , Reeder, Craig B. , Novak, Anne J. , McPhail, Ellen D. , Viswanatha, David S., Witzig, Thomas E. , Go, Ronald S. , Leung, Nelson , Lin, Yi , Thompson, Carrie A. , Hayman, Suzanne R. , Kyle, Robert A. , Kumar, Shaji , Kapoor, Prashant , LaPlant, Betsy R, Gonsalves, Wilson , Witzig, T.E. , Go, Ronald S , Buadi, Francis K. , Leung, Nelson , McPhail, Ellen Darcy , Paludo, Jonas , Dingli, David , Lin, Yi , Gertz, Morie A. , Fang, Hong , Rajkumar, S. Vincent , Habermann, Thomas M. , Dispenzieri, Angela

Mayo Clinic

American Journal of Hematology | October 28, 2017 | Volume: 93 | Issue: 2 | Pages: 187-194

10.1002/ajh.24955 | PMID 29080258 Get It

AbstractWaldenström macroglobulinemia (WM) is an immunoglobulin M‐associated lymphoma, with majority of cases demonstrating MYD88 locus alteration, most commonly, MYD88L265P. Owing to low prevalence of the wild‐type (WT) MYD88 genotype in WM, clinically relevant data in this patient population are sparse, with one study showing nearly a 10‐fold increased risk of mortality in this subgroup compared to patients with MYD88L265P mutation. We studied a large cohort of patients with MYD88L265P and MYD88WT WM, evaluated at Mayo Clinic, Rochester, between 1995 and 2016, to specifically assess the impact of these genotypes on clinical course. Of 557 patients, MYD88L265P mutation status, as determined by allele‐specific polymerase chain reaction, was known in 219, and 174 (79%) of those exhibited MYD88L265P, 157 of 174 patients had active disease. Of 45 (21%) patients with MYD88WT genotype, 44 had active disease. The estimated median follow‐up was 7.0 years; median overall survival was 10.2 years (95% CI: 8.4‐16.5) for MYD88L265P versus 13.9 years (95% CI: 6.4‐29.3) for the MYD88WT (P = 0.86). The time‐to‐next therapy from frontline treatment and the presenting features were similar in the two patient populations. For patients with smoldering WM at diagnosis, the median time‐to‐progression to active disease was 2.8 years (95% CI: 2.2‐3.8) in the MYD88L265P cohort and 1.9 years (95% CI: 0.7‐3.1) in the MYD88WT cohort (P = 0.21). The frequency of transformation to high‐grade lymphoma, or the development of therapy‐elated myelodysplastic syndrome was higher in the MYD88WT cohort (16% versus 4% in the MYD88L265P, P = 0.009). In conclusion, MYD88L265P mutation does not appear to be a determinant of outcome, and its presence may not be a disease‐defining feature in WM. Our findings warrant external validation, preferably through prospective studies.
Basal-Bolus Insulin Therapy in Postoperative Inpatients with Diabetes Mellitus: Directions for Future Quality-Improvement Initiatives
Apsey, Heidi A., Glasgow, Amy E. , Castro, Janna C. , Schlinkert, Richard T., Glasgow, Amy E. , Cook, Curtiss B. , Habermann, Elizabeth B. , Glasgow, Amy E

Mayo Clinic

Future Science OA | October 25, 2017 | Volume: 4 | Issue: 1 | Pages: No page available

10.4155/fsoa-2017-0099 | PMID 29255628 Get It

Event‐free survival at 24 months captures central nervous system relapse of systemic diffuse large B‐cell lymphoma in the immunochemotherapy era
Thanarajasingam, Gita , Maurer, Matthew J. , Farooq, Umar , Johnston, Patrick B., Thompson, Carrie A. , Bennani, Nabila Nora, Ansell, Stephen M. , Porrata, Luis F. , Macon, William R. , Syrbu, Sergei , Link, Brian K. , Nowakowski, Grzegorz S. , Bennani, Nabila N, Maurer, Matthew , Link, Brian K , Farooq, Umar , Johnston, Patrick B. , Cerhan, James R. , Habermann, Thomas M. , Witzig, Thomas E. , Syrbu, Sergei

Mayo Clinic

British Journal of Haematology | September 29, 2017 | Volume: 183 | Issue: 1 | Pages: 149-152

10.1111/bjh.14922 | PMID 28961306 Get It

The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
Shi, Qian , Flowers, Christopher R. , Schmitz, Norbert , Flament, Jocelyne, Coiffier, Bertrand , group, on behalf of the SEAL, Shi, Qian , Sargent, Daniel J. , Habermann, Thomas M. , Fu, Tommy , group, on behalf of the SEAL

Mayo Clinic

The Oncologist | August 11, 2017 | Volume: 22 | Issue: 12 | Pages: 1415-1418

10.1634/theoncologist.2017-0177 | PMID 28798271 Get It

This commentary describes the progress of the SEAL [Surrogate Endpoints for Aggressive Lymphoma] research group and invites collaboration in sharing data to continue building a large database of individual patient data from multiple clinical trials in DLBCL.
The Relative Lack of Data Regarding Firearms Injuries in the United States
Zielinski, Martin D. , Glasgow, Amy E. , Habermann, Elizabeth B. , Glasgow, Amy E. , Habermann, Elizabeth , Thiels, Cornelius A. , Glasgow, Amy E

Mayo Clinic

Annals of Surgery | August 8, 2017 | Volume: 268 | Issue: 6 | Pages: e55-e56

10.1097/sla.0000000000002471 | PMID 28796015 Get It

Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia
Paludo, Jonas , Abeykoon, Jithma P. , Kumar, Shaji , Shreders, Amanda , Kourelis, Taxiarchis , King, Rebecca L. , Reeder, Craig B. , Kyle, Robert A. , Dingli, David , Lacy, Martha Q. , Lin, Yi , Warsame, Rahma , Lust, John A., Ansell, Stephen M. , Kapoor, Prashant , Buadi, Francis K. , Gonsalves, Wilson , Paludo, Jonas , Dingli, David , Lin, Yi , Ailawadhi, Sikander , Gertz, Morie A. , Leung, Nelson , Habermann, Thomas M. , Witzig, Thomas E. , Dispenzieri, Angela , Go, Ronald S. , Gonsalves, Wilson I. , Rajkumar, S. Vincent

Mayo Clinic

British Journal of Haematology | August 8, 2017 | Volume: 179 | Issue: 1 | Pages: 98-105

10.1111/bjh.14826 | PMID 28786474 Get It

SummaryThe management of Waldenström macroglobulinaemia (WM) relies predominantly on small trials, one of which has demonstrated activity of dexamethasone, rituximab and cyclophosphamide (DRC) in the frontline setting. We report on the efficacy of DRC, focusing on relapsed/refractory (R/R) patients. Ibrutinib, a recently approved agent in WM demonstrated limited activity in patients with MYD88WT genotype. Herein, we additionally report on the activity of DRC based on the MYD88L265P mutation status. Of 100 WM patients evaluated between January 2007 and December 2014 who received DRC, 50 had R/R WM. The overall response rate (ORR) was 87%. The median progression‐free survival (PFS) and time‐to‐next‐therapy (TTNT) were 32 (95% confidence interval [CI]: 15–51) and 50 (95% CI: 35–60) months, respectively. In the previously untreated cohort (n = 50), the ORR was 96%, and the median PFS and TTNT were 34 months (95% CI: 23–not reached [NR]) and NR (95% CI: 37–NR), respectively. Twenty‐five (86%) of 29 genotyped patients harbored MYD88L265P. The response rates and outcomes were independent of MYD88 mutation status. Grade ≥3 adverse effects included neutropenia (20%), thrombocytopenia (7%) and infections (3%). Similar to the frontline setting, DRC is an effective and well‐tolerated salvage regimen for WM. In contrast to ibrutinib, DRC offers a less expensive, fixed‐duration option, with preliminary data suggesting efficacy independent of the patients’ MYD88 status.